Clinical Trial Update: Study of TD101, a Small Interfering RNA (siRNA) Designed for Treatment of Pachyonychia Congenita [Phase 1]

View source ↗

Summary

Phase 1 clinical trial of TD101, an siRNA therapy, for Pachyonychia Congenita has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pachyonychia Congenita

Drugs mentioned

• TD101

Snippet

Sponsor: Pachyonychia Congenita Project | Conditions: Pachyonychia Congenita | Phase 1 | Status: COMPLETED